Here’s whether Ocular Therapeutix, Inc. (OCUL) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+2.24% over 10 days); RSI 60 — healthy momentum range; strong 1-year return of +10.6%. Concerns: trading below the 200-day MA (long-term downtrend). Currently 42.6% off its 52-week high. Score: +2/7.
OCUL is trading below its 200-day MA ($11.05) — a key warning sign the longer-term trend is under pressure. An RSI of 60.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +10.6% compares to +24.4% for SPY (trailed the market by 13.8%). The current 42.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $11,055 today
vs. S&P 500 (SPY) — same period trailed market by 13.8%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✗Above 200-day MA ($11.05)
✓Above 50-day MA ($9.02)
✓RSI(14) neutral zone (30–70) — currently 60.1
✓Positive return (+10.6%)
!Within 10% of period high (−42.6%)
Period Range $9.43
$6.23$16.44
RSI (14) 60.1
0 · OversoldOverbought · 100
Key Metrics
Price$9.43
Period Return+10.6%
Period High$16.44
Period Low$6.23
Drawdown−42.6%
MA-50$9.02
MA-200$11.05
RSI (14)60.1
Avg Volume (30d)3.3M
vs. SPYtrailed by 18.5%
Return Rank#611 of 1245
Trend Signals
Price is below the 200-day moving average ($11.05)